The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to assess the effect of Empagliflozin on lipid and glucose
metabolism as well as volume homeostasis and renal function in elderly and obese patients
with increased risk of developing heart failure. No history of established heart failure or
diabetes is allowed.
The primary hypotheses are that 6 months treatment with Empagliflozin 10 mg a day will: 1)
decrease epicardial adipose tissue volume, and 2) reduce estimated extracellular volume
compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Jacob Moller
Collaborators:
Danish Heart Foundation Herlev and Gentofte Hospital Hillerod Hospital, Denmark Rigshospitalet, Denmark University Hospital Bispebjerg and Frederiksberg